Document:

Exhibit 10.22

 

EXECUTIVE
EMPLOYMENT AGREEMENT

 

This
Employment Agreement (hereinafter referred to as the “Agreement”) is made and effective March 25, 2022, by and between
Home Bistro, Inc. (the “Company”) and Camille May (hereinafter referred to as the “Executive”).

 

NOW,
THEREFORE, the parties hereto agree as follows:

 

1.
Engagement. Company hereby agrees to employ Executive as the Company’s Chief Financial Officer, and Executive hereby accepts
such engagement in accordance with the terms of this Agreement.

 

2.
Duties of Executive. The duties of Executive shall include advising Company management and its Board of Directors concerning matters
relating to the financial management and financial organization of the Company and other projects as the Company’s board of directors
and chief executive officer request. Executive shall perform all duties in a professional, ethical, and businesslike manner. Executive
shall be required to devote such time to the affairs of the Company as shall be necessary to manage such affairs. Executive shall perform
such duties principally from offices she maintains in Austin, Texas, subject to such reasonable travel as may be required, and shall
not be required to relocate her residence.

 

3.
Compensation. Executive will be paid compensation during this Agreement as follows:

 

		a)	An
                                            annual salary of One Hundred and Twenty Thousand dollars ($120,000) through the Term (as
                                            defined herein) of this Agreement. Such salary shall be payable in installments according
                                            to the Company’s regular payroll schedule. The
                                            Board of Directors of the Company may, at its sole discretion, award Executive bonus compensation
                                            in addition to any cash or stock incentive compensation due Executive.

 

		b)	A
                                            grant of warrants to purchase up to Two Hundred and Fifty Thousand (250,000) shares of
                                            the Company’s common stock (the “Stock”) as a sign-on bonus, which shall
                                            vest immediately and shall be subject to the Lock-Up Agreement attached hereto as Exhibit
                                            B, after which Stock may be sold subject to Company’s Insider Trading policy and SEC
                                            Rule 144.”

 

		c)	Performance-based
                                            bonuses (the “Performance
                                            Bonuses”) as set forth in the Performance Bonus
                                            Plan attached hereto as Exhibit A.

 

		d)	Weekly
                                            meal packages of up to 16 meals provided by the Company at no cost to Executive.

 

    Page 1 of 10

     

    

 

4.
Benefits.

 

		a)	Vacation.
                                            Executive shall be entitled to four weeks paid vacation each year.

 

		b)	Sick
                                            Leave. Executive shall be entitled to sick leave and emergency leave according to the
                                            regular policies and procedures of Company. Additional sick leave or emergency leave over
                                            and above paid leave provided by the Company, if any, shall be unpaid and shall be granted
                                            at the discretion of the board of directors.

 

		c)	Medical
                                            and Group Life Insurance. In the event the Company offers such a plan, Company agrees
                                            to include Executive, including Executives’ immediate family, at the Executive’s
                                            option, in a group medical and hospital insurance plan the Company may offer during the term
                                            of this Agreement. Executive shall be responsible for payment of any federal or state income
                                            tax imposed upon these benefits. The offering of a group medical and hospital insurance plan
                                            is at the discretion of the Company and NOT a condition of engagement by the Executive.

 

		d)	Maternity
                                            Leave. Executive may take up to four (4) months of
                                            paid maternity leave.

 

		e)	Expense
                                            Reimbursement. Executive shall be entitled to reimbursement for all reasonable expenses,
                                            including travel and entertainment, incurred by Executive in the performance of Executive’s
                                            duties. Executive will maintain records and written receipts as required by the Company policy
                                            and reasonably requested by the board of directors to substantiate such expenses.

 

5.
Initial Term. The Initial Term of this Agreement shall commence on March 25, 2022, and it shall continue in effect
for a period of two (2) years. Thereafter, the Agreement shall be renewed upon the mutual agreement of Executive and Company.

 

6.
Termination

 

a)
The Company may terminate Executive for Cause. “Cause” shall be defined as:

 

		(i)	An
                                            act of fraud, embezzlement or theft;

 

		(ii)	A
                                            material violation of this Agreement by Executive, which is not cured within 30 days after
                                            written notice thereof; or

 

		(iii)	Executive’s
                                            death, disability, or incapacity.

 

b)
This Agreement and Executive’s engagement may be terminated by the Company’s Board of Directors at its discretion at any
time after the Initial Term.

 

    Page 2 of 10

     

    

 

c)
This Agreement may be terminated by Executive at Executive’s discretion by providing at least thirty (30) days prior written notice
to Company. In the event of termination by Executive pursuant to this subsection, Company may immediately relieve Executive of all duties
and immediately terminate this Agreement, provided that, (i) if the Executive terminated her employment without Good Reason, Company
shall pay Executive at the then applicable annual fee rate to the termination date included in Executive’s original termination
notice, and (ii) if the Executive terminated her employment for Good reason, the Company’s compensation obligations for the term
of this Agreement will survive. “Good Reason” shall be defined as:

 

		(i)	A
                                            reduction in Executive’s base salary or bonus opportunities;

 

		(ii)	A
                                            relocation of Executive’s principal place of employment by more than forty miles;

 

		(iii)	Any
                                            material breach by the Company of any material provision of this Agreement; or

 

		(iv)	A
                                            material, adverse change in the Executive’s title, authority, duties, or responsibilities
                                            (other than temporarily while the Executive is physically or mentally incapacitated or as
                                            required by applicable law).

 

d)
In the event Company is acquired, or is the non-surviving party in a merger, or sells all or substantially all of its assets, this Agreement
shall not be terminated, and Company agrees to use its best efforts to ensure that the transferee or surviving company is bound by the
provisions of this Agreement and all share grants will vest immediately.

 

7.
Notices. All notices, requests, consents, claims, demands, waivers, and other communications hereunder (each, a “Notice”)
shall be in writing and addressed to the parties at the addresses set forth below (or to such other address that may be designated by
the receiving party from time to time in accordance with this Section). All Notices shall be delivered by personal delivery, nationally
recognized overnight courier (with all fees pre-paid), email (with confirmation of transmission) or certified or registered mail (in
each case, return receipt requested, postage pre-paid). Except as otherwise provided in this Agreement, a Notice is effective only (a)
upon receipt by the receiving party, and (b) if the party giving the Notice has complied with the requirements of this Section.

 

	If to Company:	Home Bistro, Inc.
	 	Attn: Zalmi Duchman
	 	Email:
	 	 
	With a copy to:	Baker McKenzie
	 	Roger W. Bivans
	 	Email:
	 	 
	If to Executive:	Camille May
	 	Email:
	 	 
	With a copy to:	Dwyer Murphy Calvert LLP

 

8.
Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the state of Nevada.

 

    Page 3 of 10

     

    

 

9.
Headings. Headings used in this Agreement are provided for convenience only and shall not be used to construe meaning or intent.

 

10.
No Assignment. Neither this Agreement nor any or interest in this Agreement may be assigned by Executive without the prior express
written approval of Company, which may be withheld by Company at Company’s absolute discretion.

 

11.
Severability. If any term of this Agreement is held by a court of competent jurisdiction to be invalid or unenforceable, then
this Agreement, including all of the remaining terms, will remain in full force and effect as if such invalid or unenforceable term had
never been included.

 

12.
Arbitration. The parties agree that they will use their best efforts to amicably resolve any dispute arising out of or relating
to this Agreement. Any controversy, claim or dispute that cannot be so resolved shall be settled by final binding arbitration in accordance
with the rules of the American Arbitration Association and judgment upon the award rendered by the arbitrator or arbitrators may be entered
in any court having jurisdiction thereof. Any such arbitration shall be conducted in Nevada, or such other place as may be mutually agreed
upon by the parties. Within fifteen (15) days after the commencement of the arbitration, each party shall select one person to act as
arbitrator, and the two arbitrators so selected shall select a third arbitrator within ten (10) days of their appointment. Each party
shall bear its own costs and expenses and an equal share of the arbitrator’s expenses and administrative fees of arbitration.

 

[Signature
Page Follows]

 

    Page 4 of 10

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of October 26, 2021.

 

	COMPANY:	 
	 	 	 
	HOME BISTRO, INC.	 
	 	 	 
	By:	 	 
	 	Zalmi Duchman	 
	 	Chief Executive Officer	 
	 	 	 
	EXECUTIVE:	 
	 	 	 
	 	 
	 	 	 
	CAMILLE MAY	 

 

    Page 5 of 10

     

    

 

EXHIBIT
A

 

PERFORMANCE
BONUS PLAN

 

A
Performance Bonus equal to:

 

		A.	$15,000
                                            cash bonus upon the achievement of a 30% increase in annual Gross Revenue (as defined herein);

 

		B.	$15,000
                                            cash bonus upon the achievement of an annual Gross Margin (as defined herein) of 45%; and

 

		C.	$15,000
                                            cash bonus upon the achievement of an annual Operating Margin (as defined herein) of 20%.

 

		D.	If
                                            all other Performance Bonuses (A, B and C (above)) are achieved, an additional bonus of One
                                            Hundred Thousand (100,000) shares of the Company’s common stock shall be awarded.

 

For
the purposes of this Agreement, the following definitions of terms shall apply:

 

	Gross
    Revenue:	Total sales,
    including delivery income, less refunds and discounts.
	 	 
	Cost
    of Goods Sold:	The direct costs of producing,
    packaging, and delivering the goods sold, including cost of raw material, market items, credit card processing and freight.
	 	 
	Gross
    Margin:	The quotient derived by
    dividing i) the difference of Gross Revenue minus Cost of Goods Sold by (ii) Gross Revenue.
	 	 
	Operating
    Income:	Gross Revenue less i) Cost
    of Goods Sold and ii) all direct operating costs.
	 	 
	Operating Margin:	The quotient derived by dividing (i) Operating Income
    by (ii) Gross Revenue.

 

The
Performance Bonus payments shall be made within thirty (30) days after the Company’s independent accounting firm has concluded
its annual audit. If the final audit is not prepared within ninety (90) days after the end of the fiscal year, then Company shall make
a preliminary payment equal to fifty percent (50%) of the estimated amount due preliminarily determined by the independent accounting
firm, subject to payment of the balance, if any, promptly following completion of the audit by the Company’s independent accounting
firm.

 

    Page 6 of 10

     

    

 

EXHIBIT
B

 

LOCK/UP
AGREEMENT

 

This
LOCK-UP AGREEMENT (the “Agreement”) is made as of March 25, 2022 (the “Effective Date”) by and between
Home Bistro, Inc., a Nevada corporation (the “Company”), and the undersigned holder of common stock (the “Stockholder”)
of the Company.

 

WHEREAS,
to ensure the development of an orderly trading market in the Company’s common stock (“Common Stock”), the Company
and the Stockholder intend to enter into this Agreement to provide for the circumstances under which the Stockholder may sell or otherwise
dispose of shares of the Company’s securities.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, the Company and the undersigned Stockholder agree as follows:

 

1.
Prohibition on Sales or Transfers. Except as otherwise provided in this Agreement, the Stockholder, including the Stockholder’s
Affiliated Entities (as defined below), hereby agrees that for the period beginning on the Effective Date and ending eighteen (18) months
following the Effective Date (the “Lock-Up Period”), the Stockholder will not offer, sell, contract to sell, pledge, give,
donate, transfer or otherwise dispose of, directly or indirectly, any shares of Company Common Stock or securities convertible into or
exercisable for Common Stock or securities or rights convertible into or exchangeable or exercisable for any Common Stock, whether owned
by the Stockholder as the date hereof or acquired subsequent to the date hereof (collectively, the “Lock-Up Shares”), enter
into a transaction which would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in
part, any of the economic or voting consequences of ownership of such securities, whether any such aforementioned transaction is to be
settled by delivery of the Lock-Up Shares or such other securities, in cash or otherwise, or publicly disclose the intention to make
any such offer, sale, pledge or disposition, or to enter into any such transaction, swap, hedge or other arrangement (the “Lock-Up
Agreement”). As used in this Agreement “Affiliated Entities” shall mean any legal entity, including any corporation,
limited liability company, partnership, not-for-profit corporation, estate planning vehicle or trust, which is directly or indirectly
owned or controlled by the Stockholder or his or her descendants or spouse, of which such Stockholder or his or her descendants or spouse
are beneficial owners, or which is under joint control or ownership with any other person or entity subject to a lock-up agreement regarding
the Common Stock with terms substantially identical to this Agreement.

 

2.
Attempted Transfers. Any attempted or purported sale or other Transfer of any Lock-Up Shares by the Stockholder in violation or
contravention of the terms of this Agreement shall be null and void ab initio. The Company shall instruct its transfer agent to
reject and refuse to transfer on its books any Lock-Up Shares that may have been attempted to be sold or otherwise transferred in violation
or contravention of any of the provisions of this Agreement and shall not recognize any person or entity.

 

    Page 7 of 10

     

    

 

3.
Restrictions on Sales; Volume Limitations. Upon the expiration of the Lock-Up Period, the Executive may sell shares in the open
market, pursuant to an effective registration statement or an exemption from such registration (such as Rule 144 or a successor rule),
subject to the Company’s Insider Trading Policy and SEC Rule 144.

 

4.
Broker Authorization. The Stockholder hereby authorizes any and all brokers, for all accounts holding the Stockholder’s
Lock-Up Shares, to provide directly to the Company, immediately upon the Company’s request, a copy of all account statements showing
the Lock-Up Shares during the Lock-Up Period.

 

5.
Acknowledgement of Representation. The Stockholder represents and warrants to the Company that the Stockholder was or had the
opportunity to be represented by legal counsel and other advisors selected by Stockholder in connection with this Agreement. The Stockholder
has reviewed this Agreement with his, her or its legal counsel and other advisors and understands the terms and conditions hereof.

 

6.
Legends on Certificates. All Lock-Up Shares now or hereafter owned by the Stockholder, except any shares purchased in open market
transactions by Stockholders that are not affiliates (as such term is defined under securities laws) of the Company, shall be subject
to the provisions of this Agreement and the certificates representing such Lock-Up Shares shall bear the following legends:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED FOR VALUE UNLESS THEY ARE REGISTERED UNDER
THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR UNLESS THE CORPORATION RECEIVES AN OPINION OF COUNSEL SATISFACTORY TO IT, OR OTHERWISE
SATISFIES ITSELF, THAT AN EXEMPTION FROM REGISTRATION IS AVAILABLE.

.

THE
SALE, ASSIGNMENT, GIFT, BEQUEST, TRANSFER, DISTRIBUTION, PLEDGE, HYPOTHECATION OR OTHER ENCUMBRANCE OR DISPOSITION OF THE SHARES REPRESENTED
BY THIS CERTIFICATE IS RESTRICTED BY AND MA

Y
BE MADE ONLY IN ACCORDANCE WITH THE TERMS OF A LOCK-UP AGREEMENT, A COPY OF WHICH MAY BE EXAMINED AT THE OFFICE OF THE CORPORATION.

 

7.
Governing Law; Venue. All disputes arising under this Agreement shall be governed by and interpreted in accordance with the laws
of the State of Nevada, without regard to principles of conflict of laws. The Parties hereto will submit all disputes arising under this
Agreement to arbitration in Clark County, Nevada, before a single arbitrator of the American Arbitration Association (the “AAA”).
The arbitrator shall be selected by application of the rules of the AAA, or by mutual agreement of the parties, except that such arbitrator
shall be an attorney admitted to practice law in the State of Nevada. No Party hereto will challenge the jurisdiction or venue provisions
provided in this Section 8. Nothing in this Section shall limit a Party’s right to obtain an injunction for a breach of
this Agreement from a court of law. Any injunction obtained shall remain in full force and effect until the arbitrator, as set forth
in this Section fully adjudicates the dispute.

 

    Page 8 of 10

     

    

 

8.
Binding Effect. This Agreement will be binding upon and inure to the benefit of the Company, its successors and assigns and to
the Stockholder and their respective permitted heirs, personal representatives, successors and assigns.

 

9.
Entire Understanding. This Agreement sets forth the entire agreement and understanding of the parties hereto in respect of the
subject matter hereof and the transactions contemplated hereby and supersedes all prior written and oral agreements, arrangements and
understandings relating to the subject matter hereof. This Agreement may only be changed by an agreement in writing, mutually signed
by the Company and the Stockholder subject to this Agreement.

 

10.
Remedies. The parties hereto acknowledge that money damages are not an adequate remedy for violations of this Agreement and that
any party may, in such party’s sole discretion, apply to any court of competent jurisdiction for specific performance or injunctive
relief or such other relief as such court may deem just and proper in order to enforce this Agreement or prevent any violation hereof
and, to the extent permitted by applicable law, each party hereto waives any objection to the imposition of such relief. All rights,
powers and remedies provided under this Agreement or otherwise available in respect hereof, whether at law or in equity, shall be cumulative
and not alternative, and the exercise or beginning of the exercise of any thereof by any party hereto shall not preclude the simultaneous
or later exercise of any other such right, power or remedy by such party.

 

11.
Counterparts. This Agreement may be executed by facsimile and in any number of counterparts, each of which shall be deemed to
be an original, but all of which together shall constitute one and the same instrument. Each counterpart may consist of a number of copies
each signed by less than all, but together signed by all, of the parties hereto. [Signature page follows.]

 

[Signature
Page Follows]

 

    Page 9 of 10

     

    

 

IN
WITNESS WHEREOF, this Agreement has been signed as of the date first above written.

 

	COMPANY: 	 
	 	 	 
	HOME BISTRO, INC.	 
	 	 	 
	By:	 	 
	Name:	Zalman Duchman 	 
	Title:	Chief Executive Officer	 
	 	 	 
	STOCKHOLDER: 	 
	 	 	 
	 	 
	 	 	 
	CAMILLLE MAY	 

 

Telephone
Number of Stockholder:

Email Address
of Stockholder:

Address for
Notice of Stockholder:

Address for
Delivery of Shares for Stockholder (if not same as address for notice):

 

 

Page
10 of 10EX-10.1

 Exhibit 10.1 

CONSULTING AGREEMENT 

This Consulting Agreement (the “Agreement”) is entered into and effective as of September 23, 2022 (the “Effective
Date”) by and between Cecilia Jones (“Consultant”), located at [***], and LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”), with its principal place of business at 65 Hayden Avenue,
Floor 2, Lexington, MA 02421, USA. Consultant shall provide the Consulting Services (defined below) on behalf of Consultant under this Agreement. Consultant and LogicBio shall be referred to individually as a “Party” and together as
the “Parties.” 
  

	1.	 Consulting Services. This Agreement sets forth the general terms whereby Consultant will provide
to LogicBio the consulting services described in the statements of work hereunder (collectively, the “Statements of Work”) and incorporated by reference (the “Consulting Services”). To the extent any terms set forth in the
Statements of Work conflict with the terms set forth in this Agreement, the terms of this Agreement will control unless it is otherwise specifically set forth in a Statement of Work that certain terms in any such Statement of Work will control.

  

	2.	 Compensation and Payment. 

 

	 	A.	 In consideration for Consultant’s performance of the Consulting Services, LogicBio shall pay Consultant
the fees specified in, or calculated in accordance with, the applicable Statement of Work. 

  

	 	B.	 Consultant shall submit invoices to LogicBio in accordance with the schedule specified in the applicable
Statement of Work. Invoices shall include a detailed description of the Consulting Services performed by Consultant during the period covered by the invoice as well as a reference to the Purchase Order number provided to Consultant by the Company.
If the applicable Statement of Work contemplates an hourly rate and Consultant is providing Consulting Services for a variety of projects, Consultant’s invoices shall indicate the amount of time spent on each project separately. All invoices
must be sent to LogicBio as specified in this Agreement. 

  

	 	C.	 Consultant further acknowledges and agrees that Consultant is solely responsible for the payment of all foreign
or domestic taxes, such as income tax, gross receipts tax, and foreign withholding tax, imposed on account of payment of fees made to the Consultant pursuant to this Agreement. Consultant expressly agrees to treat any compensation or fees earned
under this Agreement as self-employment income for federal and state income taxes, unemployment insurance taxes, disability insurance taxes or any other taxes when such amounts become due and payable. 

 

	 	D.	 LogicBio shall make payment to Consultant within thirty (30) days upon LogicBio’s receipt from
Consultant of invoices satisfying the requirements in Section 2 of this Agreement, unless otherwise specified in the applicable Statement of Work or as otherwise agreed to in writing by the Parties. 

 

	3.	 Reimbursement for Expenses. 

 

	 	A.	 LogicBio shall reimburse Consultant for the pre-approved, reasonable, out-of-pocket expenses specified below and incurred by Consultant during the performance of the Consulting Services under this Agreement. 

 

	 	B.	 LogicBio shall reimburse Consultant for the expenses contemplated in Section 3A within thirty
(30) days of receipt of Consultant’s invoice plus all required receipts or invoices. 

  
 Page 1 of 10 

	 	C.	 Consultant shall not submit, and LogicBio shall not reimburse Consultant, for any expenses incurred by
Consultant’s spouse, guest or business associate under any circumstances. 

  

	4.	 Confidentiality; Restrictions on Publications. 

 

	 	A.	 In the course of performing the Consulting Services, Consultant may be given, or have access to, information of
LogicBio or its affiliates (the “LogicBio Group”) or the LogicBio Group’s business partners that the LogicBio Group or its business partners consider confidential and/or proprietary, including, but not limited to, information relating
to pricing, marketing strategies and tactics, products, processes, methods, techniques, formulas, compositions, compounds, financial data, personal data, computer programs, customer and supplier lists, contacts or knowledge of customers or
prospective customers of the LogicBio Group, clinical research and development, clinical trial data, and/or the approval, administration, use or experience of any or all of LogicBio Group or LogicBio Group’s business partners’ products
(whether approved or in development), all of which information is considered confidential by LogicBio and of irreplaceable value (collectively, “Confidential Information”). 

 

	 	B.	 Consultant hereby agrees to use such Confidential Information, whether prepared by Consultant or otherwise
coming into Consultant’s possession, solely to render the Consulting Services pursuant to this Agreement. Consultant further agrees that all files, documents, records and similar items relating to any Confidential Information, whether prepared
by Consultant or otherwise coming into Consultant’s possession, shall be and remain the Confidential Information of LogicBio. During the term of this Agreement and for a period of two (2) years from the date of the Agreement’s
termination or expiration, Consultant shall not use or disclose to any third Party any Confidential Information including the existence and the terms of this Agreement without LogicBio’ prior written consent. Notwithstanding anything to the
contrary in this Agreement, obligations of confidentiality and non-use with respect to any Confidential Information identified as a trade secret by LogicBio shall remain in place for so long as the applicable
Confidential Information retains its status as a trade secret under applicable law. 

  

	 	C.	 At any time, upon request by LogicBio, or immediately on the expiration or earlier termination of this
Agreement, whichever event occurs first, Consultant shall return to LogicBio all originals and copies of Confidential Information, including, but not limited to, any files, notes, memoranda, documents, records, analyses, any and all excerpts or
other similar items, whether in written, electronic or other format. 

  

	 	D.	 Consultant shall not publish, nor submit for publication, any document describing, incorporating, resulting
from, or otherwise related to the performance of the Consulting Services and/or Confidential Information without obtaining LogicBio’s prior written consent. 

 

	 	E.	 Consultant’s obligations under this Section 5 shall not apply to any Confidential Information that
(i) is or becomes known to the general public under circumstances involving no breach by Consultant or others of the terms of this Section 5, (ii) is approved for public release by written authorization of an officer of the LogicBio Group,
(iii) at the time of disclosure is, or thereafter becomes, available to the Consultant from a third-party source on a non-confidential basis, provided that such third party is not and was not

  
 Page 2 of 10 

	 	
prohibited from disclosing such Confidential Information to Consultant by any legal, fiduciary or contractual obligation, (iv) was known by or in the possession of the Consultant, as
established by documentary evidence, prior to being disclosed by or on behalf of the LogicBio Group in connection with the Consulting Services, or (v) was or is independently developed by Consultant, as established by documentary evidence,
without reference to or use of, in whole or in part, any Confidential Information. If the Consultant is required by law or regulation to disclose any Confidential Information, the Consultant shall: (x) notify the LogicBio Group as promptly as
practicable in writing of such requirement so that the LogicBio Group may seek a protective order or other appropriate remedy, (y) furnish only that portion of the Confidential Information which the Consultant is legally required to disclose,
in accordance with advice of counsel, and (z) exercise all reasonable efforts to obtain reliable assurances that confidential treatment will be accorded to such Confidential Information. The Consultant shall, at the expense of the LogicBio
Group, cooperate with the LogicBio Group in its efforts to obtain a protective order or reliable assurance that only the designated portion of the Confidential Information shall be disclosed. 

 

	5.	 Intellectual Property. All inventions, discoveries, information, data, concepts, deliverables,
reports, innovations or other intellectual property (collectively, “Intellectual Property”) that may arise from Consultant’s performance of the Consulting Services shall be promptly disclosed to LogicBio, and title thereto shall
immediately vest in LogicBio or such designated member of the LogicBio Group. Consultant hereby assigns to LogicBio all of Consultant’s rights to and interest in any Intellectual Property. Consultant agrees that all information and written
materials prepared in the performance of the Consulting Services to be “works for hire” and copyright therein shall immediately vest in LogicBio or such designated member of the LogicBio Group. During the term of this Agreement and
thereafter, Consultant agrees to cooperate fully with, and assist LogicBio in filing, prosecuting patent, trademark and/or copyright applications and otherwise protecting LogicBio’s rights to the Intellectual Property described in this Section.
In this regard, Consultant agrees to execute any assignments and other documents as LogicBio deems necessary to protect its rights to any such Intellectual Property. LogicBio and Consultant agree that LogicBio shall have no rights in any
publication, invention, discovery, improvement, or other intellectual property whatsoever, whether or not publishable, patentable, or copyrightable, developed by Consultant in whole or in part in connection with Consultant’s employment
activities with Agios Pharmaceuticals, Inc. 

  

	6.	 Independent Contractor. LogicBio and Consultant agree that Consultant’s status under this
Agreement shall be that of an independent contractor and that Consultant is not an agent or employee of LogicBio. Consultant acknowledges and agrees that Consultant is not entitled to any benefits, coverages, or privileges, including, without
limitation, social security, unemployment, medical or pension payments, paid time off, tax withholding or other benefits routinely provided to employees. 

  

	7.	 Consultant Representation, Warranties and Covenants. 

 

	 	A.	 Consultant represents, warrants and covenants that Consultant: (i) shall use best efforts and all due
diligence in performing the Consulting Services; (ii) shall perform the Consulting Services in conformity with generally accepted professional standards; (iii) shall perform the Consulting Services without resort to any delegate or
assignee without prior written consent of LogicBio; (iv) shall comply with all applicable laws and regulations in performing the Consulting Services; (v) is not under any existing obligation that is inconsistent with this Agreement or
would restrict or conflict with the performance of 

  
 Page 3 of 10 

	 	
Consultant’s obligations hereunder, other than Consultant’s obligation to Consultant’s new employer effective September 26, 2022, provided that Consultant has received
approval from her new employer to enter into this Agreement; (vi) has disclosed to LogicBio any potential conflict of interest in connection with the provision of Consulting Services hereunder; and (vii) shall promptly disclose to LogicBio
any such conflict that may arise during the term of this Agreement. In the event that any conflict of interest arises, LogicBio, as it deems necessary, shall have the right to terminate this Agreement and/or require Consultant to refrain from
performing any portion of the Consulting Services related to the conflict of interest. Nothing in this Section shall be construed so as to relieve Consultant of any of his/her obligations under this Agreement. 

 

	 	B.	 Consultant represents and warrants that Consultant is not affiliated with the U.S. Department of Veterans
Affairs, the National Institutes of Health or any other federal, state, or local government institution, or, if Consultant is so affiliated, Consultant has provided a signed acknowledgement form of an authorized official from said institution before
executing this Agreement. 

  

	 	C.	 Consultant will not use the facilities, equipment, materials, funds, resources or proprietary information owned
or operated by any third-party organization or institution (“Institution”) or located on the Institution’s premises to perform the Consulting Services. Consultant will not engage or employ students or researchers or other employees of
an Institution to perform the Consulting Services. 

  

	 	D.	 Consultant represents and warrants that Consultant has disclosed, or shall disclose in writing prior to
executing this Agreement, to any formulary or clinical practice guidelines committee upon which Consultant may sit that Consultant is being compensated by LogicBio for consulting services. 

 

	8.	 Term and Termination. 

 

	 	A.	 The term of this Agreement shall take effect on the Effective Date and shall continue for three
(3) months from the Effective Date when it will automatically expire. 

  

	 	B.	 Either party may terminate this Agreement with fifteen (15) days written notice. During such notice
period, Consultant shall continue to perform the Consulting Services unless otherwise requested by LogicBio. 

  

	 	C.	 Either Party may terminate this Agreement immediately upon written notice to the other Party if said other
Party commits a material breach of any term hereof which is not cured to the satisfaction of the non-breaching Party within fifteen (15) days of written notice of said breach. 

 

	9.	 Debarment; Exclusion. Consultant represents and warrants that neither Consultant, nor any person
or entity authorized to assist Consultant in the performance of the Consulting Services has ever been and is not currently debarred, suspended, or excluded from, proposed for debarment, suspension, or exclusion from, or otherwise ineligible for the
award of contracts by any federal agency or participation in any federal health care program. Consultant’s representation and warranty hereunder includes, but is not limited to, debarment under Section 306(a) or (b) of the federal
Food, Drug, and Cosmetic Act, exclusion from participation in any federal health care program (as defined in 42 U.S.C. § 1320a–7b(f)) under 42 U.S.C. § 1320a-7(a) or (b), or exclusion by any
federal government agency from receiving federal contracts or federally approved subcontracts under the Federal Acquisition Regulations (FAR) or supplements thereto. 

  
 Page 4 of 10 

	10.	 Receipt of Reportable Information by Consultant. Consultant shall comply with the safety
reporting obligations set forth in Exhibit A attached and incorporated by reference. 

  

	11.	 Injunctive Relief. Without limiting LogicBio’s remedies in any way, Consultant agrees that
LogicBio shall be entitled to injunctive relief to prevent any actual or threatened breach or continuing breaches by Consultant of this Agreement since such actual or threatened breach would cause irreparable harm to LogicBio that could not
reasonably or adequately be compensated by damages in an action of law. 

  

	12.	 Publicity. Consultant (including any of his or her representatives or agents) will not make any
press release, statement or public announcement (including by means of advertising or sales promotional materials) concerning this Agreement or the subject matter of this Agreement, unless such announcement is agreed in writing in advance by
LogicBio. Neither Party will use the name or logo of the other Party without such Party’s prior written consent. 

  

	13.	 Liability and Indemnification. LogicBio shall not be liable for any loss, injury or damage
incurred by Consultant or by a third Party as a result of Consultant’s performance of the Consulting Services, including any loss, injury or damage resulting from the grossly negligent or willful act or omission by Consultant. Consultant shall
indemnify and hold LogicBio harmless from any liability, loss, cost and expense (including attorneys’ fees and costs) incurred by LogicBio as a result of Consultant’s grossly negligent or willful acts or omissions or material breach of
this Agreement. Consultant shall ensure that it fully complies with the terms of this Agreement. 

  

	14.	 Rights Under Agreement. Neither the expiration nor the earlier termination of this Agreement
shall affect in any way the rights and obligations of either Party which have accrued prior to such event or in connection therewith. The obligations and rights contained in Sections 4 (“Confidentiality; Restrictions on Publications”), 5
(“Intellectual Property”), 7 (“Consultant Representation, Warranties and Covenants”), 10 (“Receipt of Reportable Information by Consultant”), 12 (“Injunctive Relief”), 13 (“Liability and
Indemnification”) and 25 (“Governing Law) of this Agreement shall survive the expiry or earlier termination of this Agreement. 

  

	15.	 Third-Party Obligations. 

 

	 	A.	 Consultant acknowledges that the LogicBio Group from time to time may have agreements with government agencies
that impose obligations or restrictions on the LogicBio Group regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. Consultant agrees to be bound by all such obligations and
restrictions known to Consultant and to take all action necessary to discharge the obligations of the LogicBio Group under such agreements. By signing this Agreement, Consultant consents to the LogicBio Group: 

 

	 	(i)	 Collecting, processing and storing Consultant’s information, including his or her contact details, and the
payments and transfers of value made to the Consultant under this Agreement. 

  

	 	(ii)	 Making public disclosures of such information in accordance with the applicable laws, regulations or codes of
conduct. Such disclosures may be made using any media (paper or electronic), web-site or platform, including an industry association’s electronic platform. The information to be published will clearly
identify the Consultant and the types of transfers of value he or she received from LogicBio. 

  
 Page 5 of 10 

	 	(iii)	 Disclosing such information to pharmaceutical industry associations and/or competent authorities for compliance
with applicable laws, regulations or codes of conduct. 

  

	16.	 Privacy. Consultant shall comply with the provisions of the Privacy and Security Addendum
attached hereto and incorporated by reference as Exhibit B. 

  

	17.	 Notice and Notification. 

 

	 	A.	 Consultant shall promptly notify LogicBio in writing if any of the representations and warranties made by
Consultant under this Agreement become untrue or if Consultant becomes aware of any fact or circumstance which is reasonably expected to make any such representation or warranty become untrue. 

 

	 	B.	 All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in
writing and shall be deemed to have been given (i) when delivered by hand (with written confirmation of receipt); (ii) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (iii) on the date
sent by email (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient or (iv) on the fifth (5th) day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid to the following address: 

 

					
	If to LogicBio:	  	LogicBio Therapeutics, Inc.
		  	65 Hayden Avenue
		  	Lexington, MA 02421, USA
		  	Attn:	  	Frederic Chereau
		  	Email:	  	 [***]

		
	With a copy to:	  	LogicBio Therapeutics, Inc.
		  	65 Hayden Avenue
		  	Lexington, MA 02421, USA
		  	Attn:	  	Legal
		  	Email:	  	[***]
		
	If to Consultant:	  	Address and e-mail set forth in signature page

  

	21.	 Assignment. Neither Party may assign all or any part of this Agreement without the prior written
consent of the other Party; provided, however, that LogicBio may assign this Agreement to a corporate affiliate or to a successor to all or substantially all of its business without obtaining prior written consent from Consultant. This Agreement
shall be binding upon, and inure to the benefit of, both Parties and their permitted successors and assigns. 

  

	23.	 Entire Agreement. This Agreement, including the Statements of Work and exhibits, any subsequent
Statements of Work and/or exhibits, sets forth the entire agreement and understanding of the Parties with respect to the subject matter described herein and supersedes all prior written or oral agreements relating to said subject matter. In the
event of any inconsistency between the provisions of this Agreement and the Statements of Work and exhibits, the provisions of this 

  
 Page 6 of 10 

	 	
Agreement shall govern. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise in any one or more instances shall be deemed to be or construed as further
or continuing waiver of any such term, provision or condition, or of any other term, provision or condition. 

  

	24.	 Amendments. This Agreement may not be amended except in writing signed by duly authorized
representatives of both Parties. 

  

	25.	 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of
the Commonwealth of Massachusetts without regard to its conflict of laws provisions. Each Party agrees to submit to the exclusive jurisdiction of the courts of Boston, Massachusetts over any claim or matter arising under or in connection with this
Agreement. 

  

	26.	 Severability. If any one or more of the provisions of this Agreement shall, for any
reason, be held invalid, illegal or unenforceable in any respect, it shall not affect any other term or provision of this Agreement. If any provision in this Agreement shall be held to be excessively broad, it shall be construed by limiting it so as
to be enforceable to the extent compatible with applicable law. 

 *    *     *

 The foregoing is acknowledged, understood and agreed to effective as of the Effective Date as evidenced by execution of an authorized
representative of each Party in the spaces below. 
  

									
	Cecilia Jones	  		  	LogicBio Therapeutics, Inc.
				
	 /s/ Cecilia Jones
	  		  	 By:
	  	 /s/ Frederic Chereau

	            Signature	  	        	  		  	Signature
					
	 Address:
	  	 [***]
	  		  	 Name:
	  	 Frederic Chereau

	 Email:
	  	[***]	  		  	 Title:
	  	 President and Chief Executive Officer

  
 Page 7 of 10 

 Statement of Work No. 1 

 

	1.	 Description of Consulting Services: Consultant shall provide the following services to
LogicBio: 

 Assist with transitional financial matters relating to Consultant’s duties as an employee. 

 

	2.	 Compensation: In consideration for the Services performed by Consultant under this Agreement,
LogicBio shall compensate Consultant one dollar ($1) per day. 

 Consultant’s rights and obligations with respect to
any stock options or other equity granted to Consultant by the Company shall be governed by the LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan (the “Equity Plan”), as amended from time to time, and the equity award agreements by
and between Consultant and the Company evidencing such equity (collectively, the “Award Agreements”). Consultant shall be deemed to have continuously been under “Employment” (as defined in the 2018 Equity Incentive Plan) with
LogicBio from her initial date of employment with LogicBio through the termination of this Agreement and all other terms of her stock options or other equity awards shall continue to apply in accordance therewith. 

 

	3.	 LogicBio Representative: 

Frederic Chereau, President and Chief Executive Officer ([***]) 
  

	4.	 Invoices; Schedule: All of Consultant’s invoices should be sent to Accounts Payable.

 LogicBio encourages all invoices to be sent via email whenever possible. 

Accounts Payable 
 LogicBio
Therapeutics, Inc. 
 65 Hayden Ave., Floor 2 

Lexington, MA 02421 

Email: [***] 

  
 Page 8 of 10 

 Exhibit A 

Receipt of Reportable Information 
  

	A.	 To the extent any Consulting Services performed by Consultant result in Consultant’s collection, receipt
or other form of knowledge of any information about LogicBio’s drug products (collectively, “Product(s)”), from any source, in any form, relating to: an adverse event or experience (collectively, “Adverse Event”), Product
Complaint, or any other safety data or event that are required to be reported under applicable laws and/or LogicBio’s policies and procedures (collectively “Reportable Information”), Consultant shall comply with any such obligations,
including the requirements in Section B below. 

 The term “Adverse Event” shall mean any untoward medical
occurrence in a patient or clinical trial subject administered a Product and which does not necessarily have a causal relationship with this treatment. An Adverse Event can therefore be any unfavorable and unintended sign (e.g. an abnormal
laboratory finding), symptom, or disease temporarily associated with the use of a Product, whether or not considered related to the Product. 

The term “Product Complaint” shall mean any written, electronic or oral communication that alleges deficiencies related to the
identity, quality, safety, or effectiveness of a drug Product that has been released for distribution. 
  

	B.	 Consultant shall preserve the original record of any Reportable Information and within one (1) business
day but no later than (3) calendar days on which such Reportable Information was received (whether by postal mail, fax, email, phone, or voicemail) or otherwise became known to Consultant, Consultant shall submit a copy of such record and
information to LogicBio, including, to the extent legally permissible: (a) the identification and contact information for both the person receiving the Reportable Information and the person submitting such Reportable Information to LogicBio;
(b) the date on which Consultant received the Reportable Information; and (c) the identification of the Product(s) in question and all known facts regarding the event underlying the Reportable Information. 

  
 Page 9 of 10 

 Exhibit B 

Privacy and Security Addendum 
  

	1.	 Personal Data. The term “Personal Data” means any information that is processed under this
Agreement that identifies or that, together or in connection with other information, can be uniquely linked to an individual. 

  

	2.	 Personal Data processed by Consultant under this Agreement 

 

	 	a.	 Consultant represents, warrants and covenants that Consultant will process any Personal Data in compliance with
all applicable privacy and data protection laws. Consultant shall hold confidential all Personal Data. 

  

	 	b.	 When Personal Data is no longer necessary for the performance of the Consulting Services, or upon termination
of this Agreement, Consultant shall, at LogicBio’s option, securely destroy or return to LogicBio all Personal Data, unless prohibited by applicable laws. 

 

	 	c.	 Consultant will notify LogicBio as soon as practicable, but no later than twenty-four (24) hours after
Consultant becomes aware that the security, confidentiality or integrity of Personal Data has been compromised and Consultant will fully cooperate with LogicBio to comply with any obligations that arise from the unauthorized access of the Personal
Data. 

  

	 	d.	 Consultant shall cooperate with LogicBio in the course of any investigation of, or claim against, LogicBio or
its affiliates relating to the processing of Personal Data. 

  

	3.	 Personal Data about Consultant that LogicBio may process under this Agreement 

 

	 	a.	 Consultant hereby acknowledges that LogicBio (the data controller) and vendors acting on Consultant’s
behalf, in order to assist with the Consulting Services provided hereunder, may collect, use, store and disclose Consultant’s Personal Data provided or collected under this Agreement. 

 

	 	b.	 Information Consultant provides to LogicBio, its affiliates or vendors acting on their behalf for purposes of
this Agreement may be transferred to the United States and other countries which may not provide the same level of protection of Personal Data as provided where the Consultant resides. LogicBio will handle Personal Data in accordance with LogicBio
policies and applicable law regardless of where Personal Data is processed. 

  

	 	c.	 Personal Data collected and processed for purposes of this Agreement shall be processed and stored by LogicBio
for as long as is necessary to fulfill the purposes of this Agreement. 

  

	 	d.	 Consultant can send questions regarding the processing of Consultant’s Personal Data to
privacy@logicbio.com. 

  
 Page 10 of 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]